<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926496</url>
  </required_header>
  <id_info>
    <org_study_id>LP0041-63</org_study_id>
    <secondary_id>2012-003112-31</secondary_id>
    <nct_id>NCT01926496</nct_id>
  </id_info>
  <brief_title>Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%</brief_title>
  <official_title>A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or&#xD;
      other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream.&#xD;
      Subjects will be randomised to treatment with ingenol mebutate or imiquimod and will receive&#xD;
      a second treatment cycle with the same treatment if the first treatment does not clear all&#xD;
      AKs. Subjects will be followed over a period of three year (36 months) after first treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2013</start_date>
  <completion_date type="Actual">July 11, 2019</completion_date>
  <primary_completion_date type="Actual">July 11, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SCC</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative incidence of SCC after treatment with ingenol mebutate gel and imiquimod cream.&gt; The primary response criterion is diagnosis of SCC (defined as invasive SCC i.e. excludes SCC in situ) in the treatment field across the 3-year trial period.&gt; Kaplan-Meier estimate based on time to SCC or censoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of SCC and Other Neoplasia</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative incidence of SCC and other neoplasia after treatment with ingenol mebutate gel and imiquimod cream.&gt; The secondary response criterion is diagnosis of SCC and other neoplasia in the treatment field across the 3-year trial period.&gt; Kaplan-Meier estimate based on time to SCC and other neoplasia, or censoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Clearance of AK Lesions After Last Treatment</measure>
    <time_frame>8-16 weeks</time_frame>
    <description>To compare the complete clearance of AK lesions in the selected treatment area after the last treatment cycle (at Week 8 or 16)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partial Clearance of AK Lesions</measure>
    <time_frame>8-16 weeks</time_frame>
    <description>To compare the partial (at least 75%) clearance of AK lesions in the selected treatment area after the last treatment cycle (at Week 8 or 16)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Clearance of AK Lesions at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the complete clearance of AK lesions at 12 months, defined as no AK lesions in the selected treatment area at any time from the last treatment cycle at Week 8 or 16 through to Month 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Actinic Keratosis (AK)</condition>
  <arm_group>
    <arm_group_label>Ingenol Mebutate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol Mebutate Gel, 0.015%</intervention_name>
    <description>Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
    <arm_group_label>Ingenol Mebutate</arm_group_label>
    <other_name>Picato®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod Cream, 5%</intervention_name>
    <description>Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
    <arm_group_label>Imiquimod</arm_group_label>
    <other_name>Aldara®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form (ICF) prior to any trial-related procedures&#xD;
&#xD;
          2. Subjects with 5 to 9 clinically typical, visible and discrete AKs within a contiguous&#xD;
             25 cm² treatment area on the face or scalp.&#xD;
&#xD;
          3. Subject at least 18 years of age&#xD;
&#xD;
          4. Female subjects must be of either:&#xD;
&#xD;
               1. Non-childbearing potential, or,&#xD;
&#xD;
               2. Childbearing potential, provided there is a confirmed negative urine pregnancy&#xD;
                  test&#xD;
&#xD;
          5. Female subjects of childbearing potential must be willing to use highly effective&#xD;
             methods of contraception (Pearl index &lt; 1%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Location of the selected treatment area:&#xD;
&#xD;
               -  on the periorbital skin&#xD;
&#xD;
               -  on the perioral skin/around the nostrils&#xD;
&#xD;
               -  within 5 cm of an incompletely healed wound&#xD;
&#xD;
               -  within 10 cm of a suspected BCC or SCC or other neoplasia&#xD;
&#xD;
          2. Selected treatment area lesions that have atypical clinical appearance (e.g.,&#xD;
             hypertrophic, hyperkeratotic or cutaneous horn).&#xD;
&#xD;
          3. History of SCC, BCC, malignant melanoma or other neoplasia in the selected treatment&#xD;
             area.&#xD;
&#xD;
          4. History or evidence of skin conditions other than the trial indication that would&#xD;
             interfere with evaluation of the trial medication in the selected treatment area&#xD;
&#xD;
          5. Use of ingenol mebutate and/or imiquimod in and within 5 cm of the selected treatment&#xD;
             area within 2 years prior to Screening (Visit 1)&#xD;
&#xD;
          6. Organ transplant recipients&#xD;
&#xD;
          7. Immunosuppressed subjects (for example HIV patients)&#xD;
&#xD;
          8. Female subjects who are breastfeeding.&#xD;
&#xD;
          9. Subjects who are institutionalised by court order or by the local authority&#xD;
&#xD;
         10. In the opinion of the investigator, the subject is unlikely to comply with the&#xD;
             Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf-Markus Szeimies, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Dermatologie und Allergologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers - Service de Dermatologie</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL AVICENNE - Service de Dermatologie</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan - Service de Dermatologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Albert Michallon - Service de Dermatologie, Pôle Pluridisciplinaire de Médecine</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez - CHRU de Lille - Clinique de Dermatologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone - Service de Dermatologie Vénérologie</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu - Unité Fonctionnelle de Dermatologie Cancérologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL DE L ARCHET II - Service de Dermatologie-Vénérologie</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL COCHIN TARNIER - Service de Dermatologie</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Service de Dermatologie</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU BORDEAUX - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Service de Dermatologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Saint-Etienne - Hôpital Nord</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des Armées Bégin - Clinique Dermatologique</name>
      <address>
        <city>St Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Simon</name>
      <address>
        <city>Berlin</city>
        <zip>10827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hauttumorzentrum Bochum Universitätsklinikum der Ruhr-Universität-Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Streit Bucholz</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologisches Zentrum, Am Krankenhaus 1</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund - Hautklinik</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mensingderma</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautpraxis Dr. Ina Schulze</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hauttumorzentrum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie und Allergologie, Klinikum Vest, Behandlungszentrum, Knappschaftskrankenhaus Recklinghausen,</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Hoffmann</name>
      <address>
        <city>Witten</city>
        <zip>58453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Derma Hübinger</name>
      <address>
        <city>Wuppertal</city>
        <zip>42105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <state>Cumbria</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heavitree Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton General Hospital</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monklands Hospital</name>
      <address>
        <city>Airdrie</city>
        <state>Lanarkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scunthorpe General Hospital</name>
      <address>
        <city>Scunthorpe</city>
        <state>Lincolnshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Gwent Hospital</name>
      <address>
        <city>Newport</city>
        <state>Monmouthshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <state>North Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scarborough Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>North Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cannock Chase Hospital</name>
      <address>
        <city>Cannock</city>
        <state>Staffordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Surrey Hospital</name>
      <address>
        <city>Redhill</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlands Hospital</name>
      <address>
        <city>Shoreham-by-Sea</city>
        <state>West Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's Hospital</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <results_first_submitted>July 20, 2020</results_first_submitted>
  <results_first_submitted_qc>July 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 13, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT01926496/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT01926496/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The clinical trial was performed at 44 sites in 3 countries: France, 11 sites; Germany, 15 sites; and United Kingdom, 18 sites</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ingenol Mebutate</title>
          <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
        </group>
        <group group_id="P2">
          <title>Imiquimod</title>
          <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected&gt; treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In total, 485 subjects were randomised (full analysis set), but 1 subject (randomised in United Kingdom) was not treated. To support the primary safety endpoints, all baseline and safety results are based on the 484 subjects. Efficacy analysis are based on all 485 randomized subjects due to the intention-to-treat principle.</population>
      <group_list>
        <group group_id="B1">
          <title>Ingenol Mebutate</title>
          <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
        </group>
        <group group_id="B2">
          <title>Imiquimod</title>
          <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected&gt; treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="240"/>
            <count group_id="B2" value="244"/>
            <count group_id="B3" value="484"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="7.1"/>
                    <measurement group_id="B2" value="72.0" spread="8.0"/>
                    <measurement group_id="B3" value="72.3" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of SCC</title>
        <description>Cumulative incidence of SCC after treatment with ingenol mebutate gel and imiquimod cream.&gt; The primary response criterion is diagnosis of SCC (defined as invasive SCC i.e. excludes SCC in situ) in the treatment field across the 3-year trial period.&gt; Kaplan-Meier estimate based on time to SCC or censoring.</description>
        <time_frame>3 years</time_frame>
        <population>Safety analysis set: all treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate</title>
            <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod</title>
            <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected&gt; treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of SCC</title>
          <description>Cumulative incidence of SCC after treatment with ingenol mebutate gel and imiquimod cream.&gt; The primary response criterion is diagnosis of SCC (defined as invasive SCC i.e. excludes SCC in situ) in the treatment field across the 3-year trial period.&gt; Kaplan-Meier estimate based on time to SCC or censoring.</description>
          <population>Safety analysis set: all treated subjects</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.4" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of SCC and Other Neoplasia</title>
        <description>Cumulative incidence of SCC and other neoplasia after treatment with ingenol mebutate gel and imiquimod cream.&gt; The secondary response criterion is diagnosis of SCC and other neoplasia in the treatment field across the 3-year trial period.&gt; Kaplan-Meier estimate based on time to SCC and other neoplasia, or censoring.</description>
        <time_frame>3 years</time_frame>
        <population>Safety analysis set: all treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate</title>
            <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod</title>
            <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected&gt; treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8&gt;&#xD;
&gt; Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of SCC and Other Neoplasia</title>
          <description>Cumulative incidence of SCC and other neoplasia after treatment with ingenol mebutate gel and imiquimod cream.&gt; The secondary response criterion is diagnosis of SCC and other neoplasia in the treatment field across the 3-year trial period.&gt; Kaplan-Meier estimate based on time to SCC and other neoplasia, or censoring.</description>
          <population>Safety analysis set: all treated subjects</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="3.5" upper_limit="9.8"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.9" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Clearance of AK Lesions After Last Treatment</title>
        <description>To compare the complete clearance of AK lesions in the selected treatment area after the last treatment cycle (at Week 8 or 16)</description>
        <time_frame>8-16 weeks</time_frame>
        <population>Full analysis set: all randomised subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate</title>
            <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8 &gt;&#xD;
&gt; Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod</title>
            <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected&#xD;
&gt; treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8&#xD;
&gt;&#xD;
&gt; Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Clearance of AK Lesions After Last Treatment</title>
          <description>To compare the complete clearance of AK lesions in the selected treatment area after the last treatment cycle (at Week 8 or 16)</description>
          <population>Full analysis set: all randomised subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country, anatomical location and history of squamous cell carcinoma.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Cochran-Mantel-Haenszel relative risk (ingenol mebutate / imiquimod), stratified by country, anatomical location and history of squamous cell carcinoma.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partial Clearance of AK Lesions</title>
        <description>To compare the partial (at least 75%) clearance of AK lesions in the selected treatment area after the last treatment cycle (at Week 8 or 16)</description>
        <time_frame>8-16 weeks</time_frame>
        <population>Full analysis set: all randomised subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate</title>
            <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8 &gt;&#xD;
&gt; Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod</title>
            <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected&#xD;
&gt; treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8&#xD;
&gt;&#xD;
&gt; Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partial Clearance of AK Lesions</title>
          <description>To compare the partial (at least 75%) clearance of AK lesions in the selected treatment area after the last treatment cycle (at Week 8 or 16)</description>
          <population>Full analysis set: all randomised subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country, anatomical location and history of squamous cell carcinoma.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Cochran-Mantel-Haenszel relative risk (ingenol mebutate / imiquimod), stratified by country, anatomical location and history of squamous cell carcinoma.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Clearance of AK Lesions at 12 Months</title>
        <description>To compare the complete clearance of AK lesions at 12 months, defined as no AK lesions in the selected treatment area at any time from the last treatment cycle at Week 8 or 16 through to Month 12.</description>
        <time_frame>1 year</time_frame>
        <population>Full analysis set: all randomised subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate</title>
            <description>Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8 &gt;&#xD;
&gt; Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod</title>
            <description>Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected&#xD;
&gt; treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8&#xD;
&gt;&#xD;
&gt; Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Clearance of AK Lesions at 12 Months</title>
          <description>To compare the complete clearance of AK lesions at 12 months, defined as no AK lesions in the selected treatment area at any time from the last treatment cycle at Week 8 or 16 through to Month 12.</description>
          <population>Full analysis set: all randomised subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country, anatomical location and history of squamous cell carcinoma.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>Cochran-Mantel-Haenszel relative risk (ingenol mebutate / imiquimod), stratified by country, anatomical location and history of squamous cell carcinoma.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 and up to 3 years.</time_frame>
      <desc>Adverse events (AEs) were reported differently before and after Week 20. Week 20 is the first week of the follow-up period. Before Week 20, all AEs and serious AEs were recorded; after Week 20, all AEs inside the treatment area but only BCC/SCC and related SAEs outside the treatment area, were recorded.&#xD;
As per above rules, there were deaths occuring after Week 20 without an associated AE recorded. However, all deaths in the trial are included under &quot;All-Cause Mortality&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Ingenol Mebutate Until Week 20</title>
          <description>Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8.&#xD;
Ingenol Mebutate Gel, 0.015%: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.</description>
        </group>
        <group group_id="E2">
          <title>Imiquimod Until Week 20</title>
          <description>Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8 Imiquimod Cream, 5%: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs</description>
        </group>
        <group group_id="E3">
          <title>Ingenol Mebutate After Week 20</title>
          <description>Ingenol mebutate Week 20 is the first week of the follow-up period.</description>
        </group>
        <group group_id="E4">
          <title>Imiquimod After Week 20</title>
          <description>Imiquimod Week 20 is the first week of the follow-up period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <description>Source data does not describe 'number of events', only 'number of subjects'.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="240"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="240"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E3" events="56" subjects_affected="33" subjects_at_risk="240"/>
                <counts group_id="E4" events="62" subjects_affected="36" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E3" events="42" subjects_affected="24" subjects_at_risk="240"/>
                <counts group_id="E4" events="38" subjects_affected="24" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="240"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Disclosure</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 44945888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

